Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
Abstract Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases. As gut microbial imbalances and maladaptive host responses have b...
Saved in:
Main Authors: | Mette Simone Aae Madsen, Jacob Bak Holm, Albert Pallejà, Pernille Wismann, Katrine Fabricius, Kristoffer Rigbolt, Martin Mikkelsen, Morten Sommer, Jacob Jelsing, Henrik Bjørn Nielsen, Niels Vrang, Henrik H. Hansen |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/7cc76709e4214ac29b3c51f8c12f05a0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting GLP-1 receptor trafficking to improve agonist efficacy
by: Ben Jones, et al.
Published: (2018) -
Role and development of GLP-1 receptor agonists in the management of diabetes
by: Chee W Chia, et al.
Published: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Lisa M Neff, et al.
Published: (2010) -
Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
by: Shunsuke Kato, et al.
Published: (2021)